Using smart insulin pens to improve diabetes management in dependent patients
Impact of Smart Connected Insulin Pens on Quality of Life in Dependent Patients with Diabetes Using Continuous Glucose Measurement
This study is testing if smart insulin pens and continuous glucose monitors can help caregivers manage diabetes better for patients in nursing homes and reduce problems like low blood sugar.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Sud Francilien Academic / other |
| Locations | 1 site (Corbeil-Essonnes, France) |
| Trial ID | NCT06192940 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how smart connected insulin pens and continuous glucose monitoring can enhance insulin therapy for dependent or institutionalized patients with diabetes. It focuses on identifying and addressing the misuse of insulin therapy by caregivers, particularly in nursing homes where hypoglycemia is prevalent. By equipping patients with continuous glucose measurement systems and connected pens, the study seeks to provide insights into improving glycemic control and reducing hospitalizations due to insulin mismanagement.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with type 1 or type 2 diabetes who require multiple insulin injections and are dependent on health professionals for their treatment.
Not a fit: Patients who are not dependent on caregivers for insulin management or those who refuse to participate in the study may not benefit.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and diabetes management for dependent patients.
How similar studies have performed: Previous studies have shown that smart connected insulin pens can improve insulin management in type 1 diabetes, suggesting potential success for this approach in dependent patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Older than 18 years patient with type 1 or 2 diabetes * Treated with multiple insulin injections * Equipped with a continuous glucose measurement system and smart connected insulin pens at least one month before * Dependent on a health professional for treatment management. * Subject informed of the study and not objecting to data collection. Exclusion Criteria: \- Patient refusing study.
Where this trial is running
Corbeil-Essonnes, France
- Centre Hospitalier Sud Francilien — Corbeil-Essonnes, France, France (Recruiting)
Study contacts
- Principal investigator: Marie BOULY, APN — Centre Hospitalier Sud Francilien
- Study coordinator: Marie BOULY, APN
- Email: marie.bouly@chsf.fr
- Phone: 01 61 69 35 93
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.